ReviewFrontiers in microbiology2014
Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications.
Review in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 4 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Risk factors for complications of Mycoplasma pneumoniae pneumonia in hospitalized children in China: a systematic review and meta-analysis.BMC pediatrics · 2024Pooled it
- Wuhu decoction combined with azithromycin for treatment ofFrontiers in pharmacology · 2024Pooled it
- Pooled it
- The role of the PM2.5-associated metals in pathogenesis of child Mycoplasma Pneumoniae infections: a systematic review.Environmental science and pollution research international · 2016Pooled it
- Effects of propofol and sevoflurane on T-cell immune function and Th cell differentiation in children with SMPP undergoing fibreoptic bronchoscopy.Annals of medicine · 2022Trial
- S100A8/A9 as a novel predictor for severe Mycoplasma pneumoniae pneumonia in children: A prospective observational study.Clinics (Sao Paulo, Brazil) · 2026Article
- Adjunctive betamethasone treatment of hypoxaemic adults hospitalised withThe Lancet regional health. Europe · 2026Article
- Article
- The Post-Pandemic Return ofJournal of clinical medicine · 2026Article
- Identification of Mycoplasma pneumoniae P1-interacting proteins by GST pull-down and analysis of its transcriptomic regulation in A549 cells.FEMS microbiology letters · 2026Article
- Comparing differences in onset and clinical manifestations between children and adults withFrontiers in public health · 2026Article
- Outcomes of Adjunctive Corticosteroid Treatment in Hypoxemic Adults Hospitalized for Mycoplasma pneumoniae Pneumonia: A Retrospective Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Development of human mycoplasma vaccines: navigating the IL-17A paradox.Frontiers in immunology · 2025Review
- The diagnostic value of lymphocyte profiling for infectious mononucleosis and mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2025Article
- The correlation between the level of cellular classification in bronchoalveolar lavage fluid of children with severe Mycoplasma pneumoniae and clinical characteristics.European journal of pediatrics · 2024Article
- Predictive value of immune-related parameters in severeTranslational pediatrics · 2024Article
- Comparison of the clinical characteristics in parents and their children in a series of family clustered Mycoplasma pneumoniae infections.BMC pulmonary medicine · 2024Article
- Risk Factors for the Development of Post-Infectious Bronchiolitis Obliterans in Children: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2022Review
- Review
- The Diagnostic Value of High-Resolution Computed Tomography Features Combined with Mycoplasma Pneumoniae Ribonucleic Acid Load Detection for Refractory Mycoplasma Pneumonia.Contrast media & molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae (Mp) is a leading cause of community acquired pneumonia. Knowledge regarding Mp pneumonia obtained from animal models or human subjects has been discussed in many different reports. Accumulated expertise concerning this critical issue has been hard to apply clinically, and potential problems may remain undiscovered. Therefore, our multidisciplinary team extensively reviewed the literature regarding Mp pneumonia, and compared findings from animal models with those from human subjects. In human beings, the characteristic pathological features of Mp pneumonia have been reported as alveolar infiltration with neutrophils and lymphocytes and lymphocyte/plasma cell infiltrates in the peri-bronchovascular area. Herein, we demonstrated the novel aspects of Mp pneumonia that the severity of the Mp pneumonia seemed to depend on the host innate immunity to the Mp, which might be accelerated by antecedent Mp exposure (re-exposure or latent respiratory infection) through up-regulation of Toll-like receptor 2 expression on bronchial epithelial cells and alveolar macrophages. The macrolides therapy might be beneficial for the patients with macrolide-resistant Mp pneumonia via not bacteriological but immunomodulative effects. This exhaustive review focuses on pathogenesis and extends to some therapeutic implications such as clarithromycin, and discusses the various diverse aspects of Mp pneumonia. It is our hope that this might lead to new insights into this common respiratory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.